IMM-0306 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase II drugs for Splenic Marginal Zone B-Cell Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMM-0306’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMM-0306 overview
IMM-0306 is under development for the treatment of relapsed and refractory B-acute lymphocytic leukemia and relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphomas including follicular lymphoma (FL), lupus nephritis, mantle cell lymphoma, mucosal lymphoma (MALT-L), splenic marginal zone b-cell lymphoma, small lymphocytic lymphoma (SLL) / chronic lymphocytic leukemia (CLL) and neuromyelitis optica spectrum disorders (NMOSDs), systemic lupus erythematosus (SLE). The drug candidate is a trifunctional bi-specific antibody. It acts by targeting CD20 and CD47. It is administered by intravenous route.
ImmuneOnco Biopharmaceuticals (Shanghai) overview
ImmuneOnco Biopharmaceuticals (Shanghai) is a biopharmaceutical company engaged in the production and commercialization of cancer immunotherapy products and address a large number of unmet medical needs for cancer patients. The company is headquartered in Shanghai City, Shanghai, China.
For a complete picture of IMM-0306’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
